Please login to the form below
biliary tract cancer
This page shows the latest biliary tract cancer news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
AstraZeneca's (AZ) Imfinzi (durvalumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat biliary tract cancer (BTC) in combination with chemotherapy, the company announced. ... London Cancer Institute, and
Latest news
-
AstraZeneca to acquire Neogene Therapeutics in $320m deal
The agreement will build the company’s pipeline of cell-based cancer treatments. ... of biliary tract cancer, advanced gastric cancer and prostate cancer, respectively.
-
AstraZeneca receives CHMP recommendations for Imfinzi, Enhertu and Lynparza
The treatments are for use in prostate, biliary tract and advanced gastric cancer. ... Imfinzi (durvalumab) has been recommended as a first-line treatment of adult patients with unresectable or metastatic biliary tract cancer in combination with
-
AstraZeneca’s Imfinzi plus chemotherapy shows promise for advanced biliary tract cancer
AstraZeneca's (AZ) Imfinzi (durvalumab) in combination with standard of care chemotherapy demonstrated ‘clinically meaningful and durable overall survival benefit' as a treatment for patients with advanced biliary tract cancer (BTC),
-
AstraZeneca’s Imfinzi plus chemotherapy accepted for Priority Review in the US
The drug combination offers biliary tract cancer patients a new treatment option. ... Susan Galbraith, executive vice president, oncology R&D, AZ, said: “people with advanced biliary tract cancer have faced poor outcomes and limited treatment options
-
AstraZeneca’s Imfinzi and tremelimumab show unprecedented survival rate in liver cancer patients
Patients diagnosed with advanced liver cancer have a 7% survival rate after five years. ... Alongside this showcase, Imfinzi data garnered from the TOPAZ-1 phase 3 trial will be presented as a demonstration of the medicine when used as a treatment for
More from news
Approximately 4 fully matching, plus 11 partially matching documents found.
Latest Intelligence
-
Surviving cancer: a new era for patients
This treatment quickly became the ‘gold standard’ for women with metastatic breast cancer. ... biliary tract cancer as well as other solid tumours.
-
Pharma deals continue to slide
Mundipharma built its oncology franchise following the acquisition of an old anti-cancer drug and the deal to license a phase 3 product for biliary tract cancer will provide a new ... CAP7.1 prodrug of etoposide at start phase 3 for second line treatment
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Italy accelerates the path towards digital therapeutics implementation
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- The speed of science and the pace of comms
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
- Improving cardiovascular disease care and awareness
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Locus Biosciences announces first patient treated in urinary tract infection trial
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
PMHub
COUCH Health
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...
Latest intelligence
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
